Jet production in ep collisions

Results obtained by the H1 and ZEUS Collaborations on jet production in photoproduction and deep-inelastic scattering are presented and compared to NLO QCD models.Comment: 5 pages, 5 figures, talk given at the XXXVIIIth Rencontres de Moriond (QCD), Les Arcs, France, March 22-29 200

A Very Forward Proton Spectrometer for H1

A new, very forward, proton spectrometer with large acceptance will be installed in the proton beam line of the H1 experiment in 2003. The spectrometer, located 220 m downstream of the interaction point, is based on the Roman Pot technique and consists of two stations in the cold section of the proton beam line. A brief description of this new device and expected physics results are presented.Comment: 15 pages, 8 figures, talk given at LISHEP 2002, Session C: Workshop on Diffractive Physics, 4-8 February 2002, Rio de Janeiro, Brazi

Single inclusive jet production and the nuclear modification ratio at very forward rapidity in proton-lead collisions with sNN\sqrt{s_{NN}} = 5.02 TeV

We present calculations of single inclusive jet transverse momentum and energy spectra at forward rapidity ($5.2\!<\!y\!<\!6.6$) in proton-lead collisions with $\sqrt{s_{NN}}$ = 5.02 TeV. The predictions are obtained with the KaTie Monte Carlo event generator, which allows to calculate interactions within the High Energy Factorisation framework. The tree-level matrix element results are subsequently interfaced with the CASCADE Monte Carlo event generator to account for hadronisation. The effects of the saturation of the gluon density, leading to suppression of the cross section, are investigated.Comment: 10 page

Deep inelastic diffractive scattering at HERA

Recent high precision measurements of deep inelastic diffractive scattering at HERA are presented in an increased region of phase space. Current models for diffractive photon dissociation are compared to the data.Comment: 6 pages, 6 figures, talk presented at QCD03, Montpellier, France, July 2-9, 200

First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes

: Background : Type 1 diabetes (T1D) is a CD4+ T cell-driven autoimmune disease characterized by the destruction of insulin-producing pancreatic β-cells by CD8+ T cells. Achieving glycemic targets in T1D remains challenging in clinical practice; new treatments aim to halt autoimmunity and prolong β-cell survival. IMCY-0098 is a peptide derived from human proinsulin that contains a thiol-disulfide oxidoreductase motif at the N-terminus and was developed to halt disease progression by promoting the specific elimination of pathogenic T cells. Methods: This first-in-human, 24-week, double-blind phase 1b study evaluated the safety of three dosages of IMCY-0098 in adults diagnosed with T1D < 6 months before study start. Forty-one participants were randomized to receive four bi-weekly injections of placebo or increasing doses of IMCY-0098 (dose groups A/B/C received 50/150/450 μg for priming followed by three further administrations of 25/75/225 μg, respectively). Multiple T1D-related clinical parameters were also assessed to monitor disease progression and inform future development. Long-term follow-up to 48 weeks was also conducted in a subset of patients. Results: Treatment with IMCY-0098 was well tolerated with no systemic reactions; a total of 315 adverse events (AEs) were reported in 40 patients (97.6%) and were related to study treatment in 29 patients (68.3%). AEs were generally mild; no AE led to discontinuation of the study or death. No significant decline in C-peptide was noted from baseline to Week 24 for dose A, B, C, or placebo (mean change − 0.108, − 0.041, − 0.040, and − 0.012, respectively), suggesting no disease progression. Conclusions: Promising safety profile and preliminary clinical response data support the design of a phase 2 study of IMCY-0098 in patients with recent-onset T1D. Trial registration: IMCY-T1D-001: ClinicalTrials.gov NCT03272269; EudraCT: 2016–003514-27; and IMCY-T1D-002: ClinicalTrials.gov NCT04190693; EudraCT: 2018–003728-35

Performance studies of the final prototype for the CASTOR forward calorimeter at the CMS experiment

We present performance results of the final prototype for the CASTOR quartz-tungsten sampling calorimeter, to be installed in the very forward region of the CMS experiment at the LHC. The energy linearity and resolution, the uniformity, as well as the spatial resolution of the prototype to electromagnetic and hadronic showers are studied with $E=$ 10--200 GeV electrons, $E=$ 20--350 GeV pions, and $E=$ 50, 150 GeV muons in beam tests carried out at CERN/SPS in 2007

Measurement of differential cross sections for top quark pair production using the lepton plus jets final state in proton-proton collisions at 13 TeV

National Science Foundation (U.S.

Particle-flow reconstruction and global event description with the CMS detector

The CMS apparatus was identified, a few years before the start of the LHC operation at CERN, to feature properties well suited to particle-flow (PF) reconstruction: a highly-segmented tracker, a fine-grained electromagnetic calorimeter, a hermetic hadron calorimeter, a strong magnetic field, and an excellent muon spectrometer. A fully-fledged PF reconstruction algorithm tuned to the CMS detector was therefore developed and has been consistently used in physics analyses for the first time at a hadron collider. For each collision, the comprehensive list of final-state particles identified and reconstructed by the algorithm provides a global event description that leads to unprecedented CMS performance for jet and hadronic tau decay reconstruction, missing transverse momentum determination, and electron and muon identification. This approach also allows particles from pileup interactions to be identified and enables efficient pileup mitigation methods. The data collected by CMS at a centre-of-mass energy of 8 TeV show excellent agreement with the simulation and confirm the superior PF performance at least up to an average of 20 pileup interactions